-
2025 FACO | Prof. Chao Chen: Building a Precision Model to Guide Immunotherapy for Liver Cancer, Looking to Broaden Validation Through Collaboration
Editor’s Note: China, Japan, South Korea and other East Asian countries share a high prevalence of hepatobiliary and pancreatic tumors, yet current treatment options still fall short of clinical needs.…
-
Professor Zhao Mingfeng: Focusing on CLL1 CAR-T to Explore New Pathways for Treating Acute Myeloid Leukemia ｜ 2025 International Cell & Immunotherapy Conference
To promote innovation in China’s cell and immunotherapy fields, deepen discussions on key scientific questions, share the latest clinical advancements, and foster global collaboration and clinical translation, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held in Hangzhou, Zhejiang, from November 13–16, 2025. The conference was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and was co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and Liangzhu Laboratory.
-
Dialogue with a CAR-T Pioneer | Prof. Pei Shanshan and Prof. Michel Sadelain Jointly Depict the Origin, Evolution, and Future Journey of Cellular Therapy
As a revolutionary technology selected among the “Top 10 Global Engineering Achievements of 2024,” CAR-T therapy marks the arrival of the cellular therapy era and brings transformative possibilities to the treatment of cancer and major diseases. During the 2025 International Conference on Cellular and Immune Therapy, a deep dialogue between Prof. Pei Shanshan from Liangzhu Laboratory and…
-
FACO China–Japan Expert Dialogue | Professors Koji Kono, Jin Li, and Xiaotian Zhang Discuss Advances in Precision Treatment for HER2-Positive Gastric Cancer and the Evolving Therapeutic Landscape with T-DXd
China, Japan, and other Asian countries represent the regions with the highest global incidence of gastric cancer. In China, most patients are still diagnosed at advanced stages, losing the opportunity for curative surgery. Effective systemic therapies are therefore critical to improving survival. In recent years, innovative therapies—particularly antibody–drug conjugates (ADCs)—have shown promising results. Among them,…
Connecting Medical Expertise through Media
